Salvador Resino

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1812664/publications.pdf

Version: 2024-02-01

269 papers	4,804 citations	136950 32 h-index	189892 50 g-index
287 all docs	287 docs citations	287 times ranked	7047 citing authors

#	Article	IF	Citations
1	Epidemiological trend of hospitalized acute and recurrent hepatitis C in Spain. Annals of Medicine, 2024, 51, 68-68.	3.8	0
2	Antibody levels to <scp>SARSâ€CoV</scp>â€2 spike protein in mothers and children from delivery to six months later. Birth, 2023, 50, 418-427.	2.2	5
3	Low antiâ€SARSâ€CoVâ€2 S antibody levels predict increased mortality and dissemination of viral components in the blood of critical COVIDâ€19 patients. Journal of Internal Medicine, 2022, 291, 232-240.	6.0	21
4	Similar humoral immune responses against the SARS-CoV-2 spike protein in HIV and non-HIV individuals after COVID-19. Journal of Infection, 2022, 84, 418-467.	3.3	7
5	Blood microbiome is associated with changes in portal hypertension after successful direct-acting antiviral therapy in patients with HCV-related cirrhosis. Journal of Antimicrobial Chemotherapy, 2022, 77, 719-726.	3.0	7
6	HCV eradication with DAAs differently affects HIV males and females: A whole miRNA sequencing characterization. Biomedicine and Pharmacotherapy, 2022, 145, 112405.	5.6	3
7	Differences in the hepatitis C virus cascade of care and time to initiation of therapy among vulnerable subpopulations using a mobile unit as pointâ€ofâ€care. Liver International, 2022, 42, 309-319.	3.9	7
8	Baseline and <scp>timeâ€updated</scp> factors in preclinical development of anionic dendrimers as successful <scp>antiâ€HIV</scp>â€1 vaginal microbicides. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2022, 14, e1774.	6.1	5
9	Reply to Pati et al. Journal of Infectious Diseases, 2022, , .	4.0	0
10	Metabolomic changes after DAAs therapy are related to the improvement of cirrhosis and inflammation in HIV/HCV-coinfected patients. Biomedicine and Pharmacotherapy, 2022, 147, 112623.	5.6	6
11	Plasma miRNA profile at COVID-19 onset predicts severity status and mortality. Emerging Microbes and Infections, 2022, 11, 676-688.	6.5	44
12	Early innate immune response triggered by the human respiratory syncytial virus and its regulation by ubiquitination/deubiquitination processes. Journal of Biomedical Science, 2022, 29, 11.	7.0	6
13	High SARS-CoV-2 Viral Load and Low CCL5 Expression Levels in the Upper Respiratory Tract Are Associated With COVID-19 Severity. Journal of Infectious Diseases, 2022, 225, 977-982.	4.0	20
14	Misdiagnosis rate among negative COVID-19 patients in real-life with Panbio COVID-19 antigen rapid test during 2021. Journal of Infection, 2022, , .	3.3	0
15	High Plasma sTNF-R1 Level Is Related to Loss of Natural HIV Control in Long-Term Elite Controllers. Frontiers in Cellular and Infection Microbiology, 2022, 12, 858872.	3.9	1
16	Environmental factors linked to hospital admissions in young children due to acute viral lower respiratory infections: A bidirectional case-crossover study. Environmental Research, 2022, 212, 113319.	7.5	2
17	Negative impact of HIV infection on broad-spectrum anti-HCV neutralizing antibody titers in HCV-infected patients with advanced HCV-related cirrhosis. Biomedicine and Pharmacotherapy, 2022, 150, 113024.	5.6	1
18	OLFM4 polymorphisms predict septic shock survival after major surgery. European Journal of Clinical Investigation, 2021, 51, e13416.	3.4	3

#	Article	IF	Citations
19	Strategies Targeting the Innate Immune Response for the Treatment of Hepatitis C Virus-Associated Liver Fibrosis. Drugs, 2021, 81, 419-443.	10.9	12
20	TRPM5 rs886277 Polymorphism Predicts Hepatic Fibrosis Progression in Non-Cirrhotic HCV-Infected Patients. Journal of Clinical Medicine, 2021, 10, 483.	2.4	1
21	The Challenging Road to Hepatitis C Virus Eradication. Journal of Clinical Medicine, 2021, 10, 611.	2.4	5
22	Successful HCV Therapy Reduces Liver Disease Severity and Inflammation Biomarkers in HIV/HCV-Coinfected Patients With Advanced Cirrhosis: A Cohort Study. Frontiers in Medicine, 2021, 8, 615342.	2.6	11
23	HCV eradication with IFN-based therapy does not completely restore gene expression in PBMCs from HIV/HCV-coinfected patients. Journal of Biomedical Science, 2021, 28, 23.	7.0	6
24	Impact of the Economic Crisis on Endocarditis Mortality in Spain: A Nationwide Study. International Journal of Health Services, 2021, , 002073142110123.	2.5	1
25	Prevalence and factors associated with SARS-CoV-2 seropositivity in the Spanish HIV Research Network Cohort. Clinical Microbiology and Infection, 2021, 27, 1678-1684.	6.0	34
26	HCV screening based on dried blood samples and linkage to care in people who use drugs: A prospective study. International Journal of Drug Policy, 2021, 92, 103134.	3.3	11
27	HIV screening and retention in care in people who use drugs in Madrid, Spain: a prospective study. Infectious Diseases of Poverty, 2021, 10, 111.	3.7	1
28	HCV Cure With Direct-Acting Antivirals Improves Liver and Immunological Markers in HIV/HCV-Coinfected Patients. Frontiers in Immunology, 2021, 12, 723196.	4.8	14
29	Detection of active hepatitis C in a single visit and linkage to care among marginalized people using a mobile unit in Madrid, Spain. International Journal of Drug Policy, 2021, 96, 103424.	3.3	10
30	Age-Adjusted Endothelial Activation and Stress Index for Coronavirus Disease 2019 at Admission Is a Reliable Predictor for 28-Day Mortality in Hospitalized Patients With Coronavirus Disease 2019. Frontiers in Medicine, 2021, 8, 736028.	2.6	4
31	Are Reduced Levels of Coagulation Proteins Upon Admission Linked to COVID-19 Severity and Mortality?. Frontiers in Medicine, 2021, 8, 718053.	2.6	7
32	IL-1R1 rs6755229 polymorphism is related to death in patients undergoing major surgery who develop septic shock: a retrospective study. Infectious Diseases, 2021, , 1-4.	2.8	0
33	CEACAM7 polymorphisms predict genetic predisposition to mortality in post-surgical septic shock patients. Journal of Microbiology, Immunology and Infection, 2021, , .	3.1	0
34	Different HCV Exposure Drives Specific miRNA Profile in PBMCs of HIV Patients. Biomedicines, 2021, 9, 1627.	3.2	2
35	DBP rs7041 and DHCR7 rs3829251 are Linked to CD4+ Recovery in HIV Patients on Antiretroviral Therapy. Frontiers in Pharmacology, 2021, 12, 773848.	3.5	0
36	Mild profile improvement of immune biomarkers in HIV/HCV-coinfected patients who removed hepatitis C after HCV treatment: A prospective study. Journal of Infection, 2020, 80, 99-110.	3.3	9

#	Article	IF	Citations
37	Persistent HIVâ€controllers are more prone to spontaneously clear HCV: a retrospective cohort study. Journal of the International AIDS Society, 2020, 23, e25607.	3.0	2
38	The PANDEMYC Score. An Easily Applicable and Interpretable Model for Predicting Mortality Associated With COVID-19. Journal of Clinical Medicine, 2020, 9, 3066.	2.4	31
39	Near normalization of peripheral blood markers in HIV-infected patients on long-term suppressive antiretroviral therapy: a caseâ€“control study. Aids, 2020, 34, 1891-1897.	2.2	4
40	Comparison of methods and characterization of small RNAs from plasma extracellular vesicles of HIV/HCV coinfected patients. Scientific Reports, 2020, 10, 11140.	3.3	22
41	MTHFR rs1801133 Polymorphism Is Associated With Liver Fibrosis Progression in Chronic Hepatitis C: A Retrospective Study. Frontiers in Medicine, 2020, 7, 582666.	2.6	4
42	Epidemic history and baseline resistance to NS5A-specific direct acting drugs of hepatitis C virus in Spain. Scientific Reports, 2020, 10, 13024.	3.3	1
43	Effects of Hepatitis C Virus (HCV) Eradication on Bone Mineral Density in Human Immunodeficiency Virus/HCV-Coinfected Patients. Clinical Infectious Diseases, 2020, 73, e2026-e2033.	5.8	2
44	Telomere Length Increase in HIV/HCV-Coinfected Patients with Cirrhosis after HCV Eradication with Direct-Acting Antivirals. Journal of Clinical Medicine, 2020, 9, 2407.	2.4	5
45	Viral RNA load in plasma is associated with critical illness and a dysregulated host response in COVID-19. Critical Care, 2020, 24, 691.	5.8	185
46	Environmental factors are associated with hospital admissions for sepsis-related pneumonia: A bidirectional case-crossover design. Environmental Research, 2020, 191, 110102.	7.5	4
47	Persistence of Clinically Significant Portal Hypertension After Eradication of Hepatitis C Virus in Patients With Advanced Cirrhosis. Clinical Infectious Diseases, 2020, 71, 2726-2729.	5.8	23
48	Epidemiological Trend of Sepsis in Patients with Hospital Admissions Related to Hepatitis C in Spain (2000â€“2015): A Nationwide Study. Journal of Clinical Medicine, 2020, 9, 1607.	2.4	2
49	IFNL3 rs12980275 Polymorphism Predicts Septic Shock-Related Death in Patients Undergoing Major Surgery: A Retrospective Study. Frontiers in Medicine, 2020, 7, 186.	2.6	1
50	Epidemiological trend of hepatitis C-related liver events in Spain (2000â€“2015): A nationwide population-based study. European Journal of Internal Medicine, 2020, 75, 84-92.	2.2	7
51	Metabolic changes during respiratory syncytial virus infection of epithelial cells. PLoS ONE, 2020, 15, e0230844.	2.5	35
52	Hepatitis C virus vaccine design: focus on the humoral immune response. Journal of Biomedical Science, 2020, 27, 78.	7.0	23
53	Innate Immune Response against Hepatitis C Virus: Targets for Vaccine Adjuvants. Vaccines, 2020, 8, 313.	4.4	12
54	Liver Stiffness Hinders Normalization of Systemic Inflammation and Endothelial Activation after Hepatitis C Virus (HCV) Eradication in HIV/HCV Coinfected Patients. Vaccines, 2020, 8, 323.	4.4	5

#	Article	IF	Citations
55	Plasma IP-10 and IL-6 are linked to Child-Pugh B cirrhosis in patients with advanced HCV-related cirrhosis: a cross-sectional study. Scientific Reports, 2020, 10, 10384.	3.3	5
56	Plasma metabolomic fingerprint of advanced cirrhosis stages among HIV/HCVâ€coinfected and HCVâ€monoinfected patients. Liver International, 2020, 40, 2215-2227.	3.9	11
57	Downregulation of A20 Expression Increases the Immune Response and Apoptosis and Reduces Virus Production in Cells Infected by the Human Respiratory Syncytial Virus. Vaccines, 2020, 8, 100.	4.4	11
58	Effects of Eradication of HCV on Cardiovascular Risk and Preclinical Atherosclerosis in HIV/HCV-Coinfected Patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2020, 83, 292-300.	2.1	5
59	Gender-based vulnerability in women who inject drugs in a harm reduction setting. PLoS ONE, 2020, 15, e0230886.	2.5	20
60	Brief Report: CYP27B1 rs10877012 T Allele Was Linked to Non-AIDS Progression in ART-NaÃ¯ve HIV-Infected Patients: A Retrospective Study. Journal of Acquired Immune Deficiency Syndromes (1999), 2020, 85, 659-664.	2.1	2
61	CD4 recovery is associated with genetic variation in IFNÎ³ and IL19 genes. Antiviral Research, 2019, 170, 104577.	4.1	7
62	National Temporal Trend Analysis of Infective Endocarditis among Patients Infected with HIV in Spain (1997â€“2014): A Retrospective Study. Journal of Clinical Medicine, 2019, 8, 1167.	2.4	4
63	European mitochondrial haplogroups predict liver-related outcomes in patients coinfected with HIV and HCV: a retrospective study. Journal of Translational Medicine, 2019, 17, 244.	4.4	6
64	Nosocomial Vs. Community-Acquired Infective Endocarditis in Spain: Location, Trends, Clinical Presentation, Etiology, and Survival in the 21st Century. Journal of Clinical Medicine, 2019, 8, 1755.	2.4	22
65	DBP rs16846876 and rs12512631 polymorphisms are associated with progression to AIDS naÃ¯ve HIV-infected patients: a retrospective study. Journal of Biomedical Science, 2019, 26, 83.	7.0	2
66	Rapid decrease in titer and breadth of neutralizing anti-HCV antibodies in HIV/HCV-coinfected patients who achieved SVR. Scientific Reports, 2019, 9, 12163.	3.3	2
67	MicroRNA Profile of HCV Spontaneous Clarified Individuals, Denotes Previous HCV Infection. Journal of Clinical Medicine, 2019, 8, 849.	2.4	11
68	IL7RA rs6897932 Polymorphism is Associated with Better CD4+ T-Cell Recovery in HIV Infected Patients Starting Combination Antiretroviral Therapy. Biomolecules, 2019, 9, 233.	4.0	9
69	Evaluation of the diagnostic accuracy of laboratory-based screening for hepatitis C in dried blood spot samples: A systematic review and meta-analysis. Scientific Reports, 2019, 9, 7316.	3.3	35
70	siRNA-Mediated Simultaneous Regulation of the Cellular Innate Immune Response and Human Respiratory Syncytial Virus Replication. Biomolecules, 2019, 9, 165.	4.0	5
71	VDR rs2228570 Polymorphism Is Related to Non-Progression to AIDS in Antiretroviral Therapy NaÃ¯ve HIV-Infected Patients. Journal of Clinical Medicine, 2019, 8, 311.	2.4	9
72	TNFAIP3, TNIP1, and MyD88 Polymorphisms Predict Septic-Shock-Related Death in Patients Who Underwent Major Surgery. Journal of Clinical Medicine, 2019, 8, 283.	2.4	5

#	Article	IF	Citations
73	Impact of DARC rs12075 Variants on Liver Fibrosis Progression in Patients with Chronic Hepatitis C: A Retrospective Study. Biomolecules, 2019, 9, 143.	4.0	7
74	Genetic variation in CCR2 and CXCL12 genes impacts on CD4 restoration in patients initiating cART with advanced immunesupression. PLoS ONE, 2019, 14, e0214421.	2.5	11
75	HCV-coinfection is related to an increased HIV-1 reservoir size in cART-treated HIV patients: a cross-sectional study. Scientific Reports, 2019, 9, 5606.	3.3	22
76	Prevalence of hepatitis E infection in HIV/HCV-coinfected patients in Spain (2012â€“2014). Scientific Reports, 2019, 9, 1143.	3.3	8
77	Lower expression of plasma-derived exosome miR-21 levels in HIV-1 elite controllers with decreasing CD4 T cell count. Journal of Microbiology, Immunology and Infection, 2019, 52, 667-671.	3.1	14
78	Genetic variants upstream of TNFAIP3 in the 6q23 region are associated with liver disease severity in HIV/HCV-coinfected patients: A cross-sectional study. Infection, Genetics and Evolution, 2019, 67, 112-120.	2.3	2
79	PNPLA3 rs738409 polymorphism is associated with liver fibrosis progression in patients with chronic hepatitis C: A repeated measures study. Journal of Clinical Virology, 2018, 103, 71-74.	3.1	10
80	Association of CD14 rs2569190 polymorphism with mortality in shock septic patients who underwent major cardiac or abdominal surgery: A retrospective study. Scientific Reports, 2018, 8, 2698.	3.3	7
81	Elevated liver stiffness is linked to increased biomarkers of inflammation and immune activation in HIV/hepatitis C virus-coinfected patients. Aids, 2018, 32, 1095-1105.	2.2	28
82	Evaluation of dried blood spot samples for screening of hepatitis C and human immunodeficiency virus in a real-world setting. Scientific Reports, 2018, 8, 1858.	3.3	34
83	Pegylated Interferon-Î±â€“Induced Natural Killer Cell Activation Is Associated With Human Immunodeficiency Virus-1 DNA Decline in Antiretroviral Therapyâ€“Treated HIV-1/Hepatitis C Virusâ€“Coinfected Patients. Clinical Infectious Diseases, 2018, 66, 1910-1917.	5.8	30
84	Frecuencia de sustituciones relevantes asociadas a resistencia en la regiÃ³n NS5A a elbasvir en el virus de la hepatitis C en pacientes con genotipo 1a en EspaÃ±a. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2018, 36, 262-267.	0.5	2
85	Epidemiological trends of deep venous thrombosis in HIV-infected subjects (1997â€“2013): A nationwide population-based study in Spain. European Journal of Internal Medicine, 2018, 48, 69-74.	2.2	3
86	Bacterial translocation and clinical progression of HCVâ€related cirrhosis in HIVâ€infected patients. Journal of Viral Hepatitis, 2018, 25, 180-186.	2.0	4
87	Mitochondrial haplogroup H is related to CD4+ T cell recovery in HIV infected patients starting combination antiretroviral therapy. Journal of Translational Medicine, 2018, 16, 343.	4.4	6
88	Trends in pulmonary embolism in patients infected with HIV during the combination antiretroviral therapy era in Spain: A nationwide population-based study. Scientific Reports, 2018, 8, 12137.	3.3	4
89	The Myeloid-Epithelial-Reproductive Tyrosine Kinase (MERTK) rs4374383 Polymorphism Predicts Progression of Liver Fibrosis in Hepatitis C Virus-Infected Patients: A Longitudinal Study. Journal of Clinical Medicine, 2018, 7, 473.	2.4	15
90	Dysregulation of the Immune System in HIV/HCV-Coinfected Patients According to Liver Stiffness Status. Cells, 2018, 7, 196.	4.1	14

#	Article	IF	Citations
91	Surgery for acute infective endocarditis: epidemiological data from a Spanish nationwide hospital-based registryâ€. Interactive Cardiovascular and Thoracic Surgery, 2018, 27, 498-504.	1.1	13
92	The IL7RA rs6897932 polymorphism is associated with progression of liver fibrosis in patients with chronic hepatitis C: Repeated measurements design. PLoS ONE, 2018, 13, e0197115.	2.5	10
93	Vitamin D in Human Immunodeficiency Virus Infection: Influence on Immunity and Disease. Frontiers in Immunology, 2018, 9, 458.	4.8	110
94	High Plasma Levels of sTNF-R1 and CCL11 Are Related to CD4+ T-Cells Fall in Human Immunodeficiency Virus Elite Controllers With a Sustained Virologic Control. Frontiers in Immunology, 2018, 9, 1399.	4.8	3
95	Epidemiological trends of sepsis in the twenty-first century (2000â€“2013): an analysis of incidence, mortality, and associated costs in Spain. Population Health Metrics, 2018, 16, 4.	2.7	51
96	Prevalence of relevant NS5A resistance-associated substitutions to elbasvir in genotype 1a hepatitis C virus patients in Spain. Enfermedades Infecciosas Y Microbiologia Clinica (English Ed), 2018, 36, 262-267.	0.3	0
97	Mx1, OAS1 and OAS2 polymorphisms are associated with the severity of liver disease in HIV/HCV-coinfected patients: A cross-sectional study. Scientific Reports, 2017, 7, 41516.	3.3	22
98	IL-6 rs1800795 polymorphism is associated with septic shock-related death in patients who underwent major surgery: a preliminary retrospective study. Annals of Intensive Care, 2017, 7, 22.	4.6	12
99	G2-S16 dendrimer as a candidate for a microbicide to prevent HIV-1 infection in women. Nanoscale, 2017, 9, 9732-9742.	5.6	25
100	ADAR1 polymorphisms are related to severity of liver fibrosis in HIV/HCV-coinfected patients. Scientific Reports, 2017, 7, 12918.	3.3	7
101	IL7RApolymorphisms are not associated with AIDS progression. European Journal of Clinical Investigation, 2017, 47, 719-727.	3.4	3
102	Low frequency of NS5A relevant resistance-associated substitutions to Elbasvir among hepatitis C virus genotype 1a in Spain: a cross-sectional study. Scientific Reports, 2017, 7, 2892.	3.3	8
103	ILâ€1B rs16944 polymorphism is related to septic shock and death. European Journal of Clinical Investigation, 2017, 47, 53-62.	3.4	17
104	CXCL9â€11 polymorphisms are associated with liver fibrosis in patients with chronic hepatitis C: a crossâ€sectional study. Clinical and Translational Medicine, 2017, 6, 26.	4.0	13
105	TRIM25 in the Regulation of the Antiviral Innate Immunity. Frontiers in Immunology, 2017, 8, 1187.	4.8	109
106	Efficacy of carbosilane dendrimers with an antiretroviral combination against HIV-1 in the presence of semen-derived enhancer of viral infection. European Journal of Pharmacology, 2017, 811, 155-163.	3.5	23
107	Stroke in HIV-infected individuals with and without HCV coinfection in Spain in the combination antiretroviral therapy era. PLoS ONE, 2017, 12, e0179493.	2.5	14
108	Liver stiffness measurement predicts liver-related events in patients with chronic hepatitis C: A retrospective study. PLoS ONE, 2017, 12, e0184404.	2.5	10

#	Article	IF	Citations
109	Genetic Polymorphisms Associated with Liver Disease Progression in HIV/HCV-Coinfected Patients. AIDS Reviews, 2017, 19, 3-15.	1.0	14
110	Soluble Adhesion Molecules in Patients Coinfected with HIV and HCV: A Predictor of Outcome. PLoS ONE, 2016, 11, e0148537.	2.5	8
111	Environmental Factors Related to Pulmonary Tuberculosis in HIV-Infected Patients in the Combined Antiretroviral Therapy (cART) Era. PLoS ONE, 2016, 11, e0165944.	2.5	34
112	Trends in Epidemiology of COPD in HIV-Infected Patients in Spain (1997â€“2012). PLoS ONE, 2016, 11, e0166421.	2.5	11
113	Optimal vitamin D plasma levels are associated with lower bacterial DNA translocation in HIV/hepatitis c virus coinfected patients. Aids, 2016, 30, 1069-1074.	2.2	7
114	IL15 polymorphism is associated with advanced fibrosis, inflammationâ€related biomarkers and virological response in human immunodeficiency virus/hepatitis C virus coinfection. Liver International, 2016, 36, 1258-1266.	3.9	5
115	Impact of patatin-like phospholipase domain-containing 3 gene polymorphism (rs738409) on severity of liver disease in HIV/hepatitis C virus-coinfected patients. Aids, 2016, 30, 465-470.	2.2	12
116	Relationship of TRIM5 and TRIM22 polymorphisms with liver disease and HCV clearance after antiviral therapy in HIV/HCV coinfected patients. Journal of Translational Medicine, 2016, 14, 257.	4.4	20
117	Impact of chronic hepatitis C on mortality in cirrhotic patients admitted to intensive-care unit. BMC Infectious Diseases, 2016, 16, 122.	2.9	5
118	Short Communication: CXCL12 rs1029153 Polymorphism Is Associated with the Sustained Virological Response in HIV/Hepatitis C Virus-Coinfected Patients on Hepatitis C Virus Therapy. AIDS Research and Human Retroviruses, 2016, 32, 226-231.	1.1	0
119	Fifteen-Year Trends in the Prevalence of Diabetes among Hospitalized HIV-Infected Patients in Spain (1997-2012). PLoS ONE, 2016, 11, e0161953.	2.5	3
120	NS3 Resistance-Associated Variants (RAVs) in Patients Infected with HCV Genotype 1a in Spain. PLoS ONE, 2016, 11, e0163197.	2.5	16
121	Relationship between ITPA polymorphisms and hemolytic anemia in HCV-infected patients after ribavirin-based therapy: a meta-analysis. Journal of Translational Medicine, 2015, 13, 320.	4.4	19
122	Association between IL7R polymorphisms and severe liver disease in HIV/HCV coinfected patients: a cross-sectional study. Journal of Translational Medicine, 2015, 13, 206.	4.4	10
123	Trends in nontuberculous mycobacterial disease in hospitalized subjects in <scp>S</scp>pain (1997â€“2010) according to <scp>HIV</scp> infection. HIV Medicine, 2015, 16, 485-493.	2.2	8
124	Reply. Hepatology, 2015, 62, 1643-1643.	7.3	2
125	<scp>IL</scp>7<scp>RA</scp> polymorphisms predict the <scp>CD</scp>4+ recovery in <scp>HIV</scp> patients on <scp>cART</scp>. European Journal of Clinical Investigation, 2015, 45, 1192-1199.	3.4	12
126	Pneumocystis pneumonia in HIVâ€positive patients in Spain: epidemiology and environmental risk factors. Journal of the International AIDS Society, 2015, 18, 19906.	3.0	23

#	Article	IF	Citations
127	Single Nucleotide Polymorphisms of CXCL9-11 Chemokines Are Associated With Liver Fibrosis in HIV/HCV-Coinfected Patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 68, 386-395.	2.1	11
128	TLR3 polymorphisms are associated with virologic response to hepatitis C virus (HCV) treatment in HIV/HCV coinfected patients. Journal of Clinical Virology, 2015, 65, 62-67.	3.1	6
129	Association between IL7RA polymorphisms and the successful therapy against HCV in HIV/HCV-coinfected patients. European Journal of Clinical Microbiology and Infectious Diseases, 2015, 34, 385-393.	2.9	4
130	Transcriptomic correlates of organ failure extent in sepsis. Journal of Infection, 2015, 70, 445-456.	3.3	81
131	Toll-like receptor 8 (TLR8) polymorphisms are associated with non-progression of chronic hepatitis C in HIV/HCV coinfected patients. Infection, Genetics and Evolution, 2015, 36, 339-344.	2.3	6
132	Mitochondrial DNA haplogroups are associated with severe sepsis and mortality in patients who underwent major surgery. Journal of Infection, 2015, 70, 20-29.	3.3	17
133	rs7903146 Polymorphism atTranscription Factor 7 Like 2Gene Is Associated with Total Cholesterol and Lipoprotein Profile in HIV/Hepatitis C Virus-Coinfected Patients. AIDS Research and Human Retroviruses, 2015, 31, 326-334.	1.1	5
134	Relationship between European Mitochondrial Haplogroups and Chronic Renal Allograft Rejection in Patients with Kidney Transplant. International Journal of Medical Sciences, 2014, 11, 1129-1132.	2.5	3
135	FTOrs9939609 polymorphism is associated with metabolic disturbances and response to HCV therapy in HIV/HCV-coinfected patients. BMC Medicine, 2014, 12, 198.	5.5	4
136	Association of adiponectin (<scp>ADIPOQ</scp>) rs2241766 polymorphism and dyslipidemia in <scp>HIV</scp>/<scp>HCV</scp>â€coinfected patients. European Journal of Clinical Investigation, 2014, 44, 453-462.	3.4	12
137	Mortality of patients infected with HIV in the intensive care unit (2005 through 2010): significant role of chronic hepatitis C and severe sepsis. Critical Care, 2014, 18, 475.	5.8	18
138	PPARÎ³2 Pro12Ala Polymorphism Is Associated With Sustained Virological Response in HIV/HCV-Coinfected Patients Under HCV Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 67, 113-119.	2.1	5
139	SLC30A8 rs13266634 polymorphism is related to a favorable cardiometabolic lipid profile in HIV/hepatitis C virus-coinfected patients. Aids, 2014, 28, 1325-1332.	2.2	9
140	Incidence and mortality of tuberculosis disease in Spain between 1997 and 2010: Impact of human immunodeficiency virus (HIV) status. Journal of Infection, 2014, 68, 355-362.	3.3	12
141	Vitamin D deficiency is associated with severity of liver disease in HIV/HCV coinfected patients. Journal of Infection, 2014, 68, 176-184.	3.3	28
142	CXCL9, CXCL10 and CXCL11 polymorphisms are associated with sustained virologic response in HIV/HCV-coinfected patients. Journal of Clinical Virology, 2014, 61, 423-429.	3.1	13
143	<scp>IL</scp>28<scp>RA</scp> polymorphism (rs10903035) is associated with insulin resistance in <scp>HIV</scp>/<scp>HCV</scp>â€coinfected patients. Journal of Viral Hepatitis, 2014, 21, 189-197.	2.0	5
144	Relationship of vitamin D status with advanced liver fibrosis and response to hepatitis C virus therapy: A meta-analysis. Hepatology, 2014, 60, 1541-1550.	7.3	68

#	Article	IF	Citations
145	PPARÎ³2 Pro12Ala polymorphism was associated with favorable cardiometabolic risk profile in HIV/HCV coinfected patients: a cross-sectional study. Journal of Translational Medicine, 2014, 12, 235.	4.4	11
146	European mitochondrial haplogroups are not associated with hepatitis <scp>C</scp> virus (<scp>HCV</scp>) treatment response in <scp>HIV</scp>/<scp>HCV</scp>â€coinfected patients. HIV Medicine, 2014, 15, 425-430.	2.2	5
147	ACSM4 Polymorphisms Are Associated With Rapid AIDS Progression in HIV-Infected Patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 65, 27-32.	2.1	8
148	FTO rs9939609 polymorphism is associated with metabolic disturbances and response to HCV therapy in HIV/HCV-coinfected patients. BMC Medicine, 2014, 12, 198.	5.5	7
149	Rate of candidiasis among HIV-infected children in Spain in the era of highly active antiretroviral therapy (1997â€“2008). BMC Infectious Diseases, 2013, 13, 115.	2.9	7
150	Meta-analysis: implications of interleukin-28B polymorphisms in spontaneous and treatment-related clearance for patients with hepatitis C. BMC Medicine, 2013, 11, 6.	5.5	80
151	Comment on: â€˜Interleukin-28 polymorphisms on the SVR in the treatment of naÃ¯ve chronic hepatitis C with pegylated interferon-Î± plus ribavirin: A meta-analysisâ€™. Gene, 2013, 522, 121.	2.2	2
152	<scp>IL</scp>28<scp>RA</scp> polymorphism is associated with early hepatitis <scp>C</scp> virus (<scp>HCV</scp>) treatment failure in human immunodeficiency virusâ€/<scp>HCV</scp>â€coinfected patients. Journal of Viral Hepatitis, 2013, 20, 358-366.	2.0	17
153	Association of torque teno virus (TTV) and torque teno mini virus (TTMV) with liver disease among patients coinfected with human immunodeficiency virus and hepatitis C virus. European Journal of Clinical Microbiology and Infectious Diseases, 2013, 32, 289-297.	2.9	37
154	IL28B polymorphisms are associated with severity ofÂliver disease in human immunodeficiency virus (HIV) patients coinfected with hepatitis C virus. Journal of Infection, 2013, 66, 170-178.	3.3	13
155	HLA-E variants are associated with sustained virological response in HIV/hepatitis C virus-coinfected patients on hepatitis C virus therapy. Aids, 2013, 27, 1231-1238.	2.2	15
156	Prediction of Hepatic Fibrosis in Patients Coinfected With HIV and Hepatitis C Virus Based on Genetic Markers. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 64, 434-442.	2.1	6
157	European mitochondrial haplogroups are associated with CD4+ T cell recovery in HIV-infected patients on combination antiretroviral therapy. Journal of Antimicrobial Chemotherapy, 2013, 68, 2349-2357.	3.0	17
158	Mitochondrial Haplogroups Are Associated With Clinical Pattern of AIDS Progression in HIV-Infected Patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 63, 178-183.	2.1	21
159	Analysis of IL28B alleles with virologic response patterns and plasma cytokine levels in HIV/HCV-coinfected patients. Aids, 2013, 27, 163-173.	2.2	12
160	Coinfection by human immunodeficiency virus and hepatitis C virus. Current Opinion in Infectious Diseases, 2012, 25, 564-569.	3.1	30
161	Plasma IL-6 and IL-9 predict the failure of interferon-Â plus ribavirin therapy in HIV/HCV-coinfected patients. Journal of Antimicrobial Chemotherapy, 2012, 67, 1238-1245.	3.0	30
162	Trend of Pneumonia Incidence Among Children Infected With HIV in the Era of Highly Active Antiretroviral Therapy. Pediatric Infectious Disease Journal, 2012, 31, 599-601.	2.0	3

#	Article	IF	Citations
163	Reduction in Mycobacterial Disease Among HIV-infected Children in the Highly Active Antiretroviral Therapy Era (1997â€“2008). Pediatric Infectious Disease Journal, 2012, 31, 278-283.	2.0	15
164	Bacterial DNA Translocation and Liver Disease Severity Among HIV-Infected Patients With Chronic Hepatitis C. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 61, 552-556.	2.1	11
165	High plasma CXCL10 levels are associated with HCV-genotype 1, and higher insulin resistance, fibrosis, and HIV viral load in HIV/HCV coinfected patients. Cytokine, 2012, 57, 25-29.	3.2	20
166	A combined score of pro- and anti-inflammatory interleukins improves mortality prediction in severe sepsis. Cytokine, 2012, 57, 332-336.	3.2	139
167	Genetic polymorphisms located in TGFB1, AGTR1, and VEGFA genes are associated to chronic renal allograft dysfunction. Cytokine, 2012, 58, 321-326.	3.2	17
168	Genetic polymorphisms located in genes related to immune and inflammatory processes are associated with end-stage renal disease: a preliminary study. BMC Medical Genetics, 2012, 13, 58.	2.1	9
169	Early natural killer cell counts in blood predict mortality in severe sepsis. Critical Care, 2011, 15, R243.	5.8	85
170	High plasma fractalkine (CX3CL1) levels are associated with severe liver disease in HIV/HCV co-infected patients with HCV genotype 1. Cytokine, 2011, 54, 244-248.	3.2	14
171	European Mitochondrial DNA Haplogroups and Metabolic Disorders in HIV/HCV-Coinfected Patients on Highly Active Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 58, 371-378.	2.1	22
172	Epidemiologic Trends of Cancer Diagnoses Among HIV-infected Children in Spain From 1997 to 2008. Pediatric Infectious Disease Journal, 2011, 30, 764-768.	2.0	21
173	Hepatitis C virus (HCV) treatment uptake and changes in the prevalence of HCV genotypes in HIV/HCVâ€coinfected patients. Journal of Viral Hepatitis, 2011, 18, 325-330.	2.0	31
174	Adipokine profiles and lipodystrophy in HIV-infected children during the first 4 years on highly active antiretroviral therapy. HIV Medicine, 2011, 12, 54-60.	2.2	12
175	Diagnostic accuracy of the APRI, FIB-4, and the Forns index for predicting liver fibrosis in HIV/HCV-coinfected patients: A validation study. Journal of Infection, 2011, 63, 402-405.	3.3	18
176	Soluble markers of inflammation are associated with Framingham scores in HIV-infected patients on suppressive antiretroviral therapy. Journal of Infection, 2011, 63, 382-390.	3.3	19
177	Soluble Fas and Fas ligand in HIV/HCV coinfected patients and impact of HCV therapy. European Journal of Clinical Microbiology and Infectious Diseases, 2011, 30, 1213-1221.	2.9	3
178	Direct association between pharyngeal viral secretion and host cytokine response in severe pandemic influenza. BMC Infectious Diseases, 2011, 11, 232.	2.9	24
179	An artificial neural network improves the non-invasive diagnosis of significant fibrosis in HIV/HCV coinfected patients. Journal of Infection, 2011, 62, 77-86.	3.3	31
180	Cardiovascular risk markers are increased in HIV-infected children with lipodystrophy syndrome. Journal of Infection, 2011, 62, 240-243.	3.3	4

#	Article	IF	Citations
181	Sustained Virologic Response Decreases Serum Markers of Angiogenesis, Inflammation, and Fibrosis in HIV/HCV-Coinfected Patients on Hepatitis C Virus Therapy. AIDS Patient Care and STDs, 2011, 25, 131-133.	2.5	2
182	Sustained virological response to interferon-Â plus ribavirin decreases inflammation and endothelial dysfunction markers in HIV/HCV co-infected patients. Journal of Antimicrobial Chemotherapy, 2011, 66, 645-649.	3.0	29
183	European mitochondrial DNA haplogroups and liver fibrosis in HIV and hepatitis C virus coinfected patients. Aids, 2011, 25, 1619-1926.	2.2	12
184	Plasma Interferon-Î³-Inducible Protein-10 Can Predict Virologic Response to Hepatitis C Virus Therapy in HIV/HCV-Coinfected Patients With HCV Genotype 1. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 54, 219-220.	2.1	5
185	ASSOCIATION BETWEEN LIPODYSTROPHY AND LEPTIN IN HUMAN IMMUNODEFICIENCY VIRUS-1-INFECTED CHILDREN RECEIVING LOPINAVIR/RITONAVIR-BASED THERAPY. Pediatric Infectious Disease Journal, 2010, 29, 774-777.	2.0	4
186	Hepatitis C virus infection is associated with endothelial dysfunction in HIV/hepatitis C virus coinfected patients. Aids, 2010, 24, 2059-2067.	2.2	39
187	Incidence of liver cirrhosis in HIV-infected patients with chronic hepatitis B or C in the era of highly active antiretroviral therapy. Antiviral Therapy, 2010, 15, 881-886.	1.0	35
188	Serum levels of adipokines in HIV/HCV co-infected patients and their association with insulin resistance and liver disease severity. Journal of Infection, 2010, 61, 499-501.	3.3	3
189	Can serum hyaluronic acid replace simple non-invasive indexes to predict liver fibrosis in HIV/Hepatitis C coinfected patients?. BMC Infectious Diseases, 2010, 10, 244.	2.9	27
190	Diagnosis of advanced fibrosis in HIV and hepatitis C virusâ€coinfected patients via a new noninvasive index: the HGMâ€3 index. HIV Medicine, 2010, 11, 64-73.	2.2	13
191	CD81 expression in peripheral blood lymphocytes before and after treatment with interferon and ribavirin in HIV/HCV coinfected patients. HIV Medicine, 2010, 11, 161-169.	2.2	3
192	Opportunistic infections and organâ€specific diseases in HIVâ€1â€infected children: a cohort study (1990â€“2006). HIV Medicine, 2010, 11, 245-252.	2.2	25
193	Association between plasma levels of eotaxin (CCL-11) and treatment response to interferon-Â and ribavirin in HIV/HCV co-infected patients. Journal of Antimicrobial Chemotherapy, 2010, 65, 303-306.	3.0	8
194	Modeling the Probability of Sustained Virological Response to Therapy with Pegylated Interferon plus Ribavirin in Patients Coinfected with Hepatitis C Virus and HIV. Clinical Infectious Diseases, 2010, 51, 1209-1216.	5.8	56
195	Insulin Resistance Impairs Response to Interferon Plus Ribavirin in Patients Coinfected With HIV and Hepatitis C Virus. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 55, 176-181.	2.1	15
196	Host adaptive immunity deficiency in severe pandemic influenza. Critical Care, 2010, 14, R167.	5.8	145
197	First evidence of a pro-inflammatory response to severe infection with influenza virus H1N1. Critical Care, 2010, 14, 115.	5.8	10
198	Increased Th1, Th17 and pro-fibrotic responses in hepatitis C-infected patients are down-regulated after 12 weeks of treatment with pegylated interferon plus ribavirin. European Cytokine Network, 2010, 21, 84-91.	2.0	31

#	Article	IF	Citations
199	Premature immunosenescence in HIV-infected patients on highly active antiretroviral therapy with low-level CD4 T cell repopulation. Journal of Antimicrobial Chemotherapy, 2009, 64, 579-588.	3.0	57
200	Rate and Timing of Hepatitis C Virus Relapse after a Successful Course of Pegylated Interferon plus Ribavirin in HIVâ€Infected and HIVâ€Uninfected Patients. Clinical Infectious Diseases, 2009, 49, 1397-1401.	5.8	35
201	Serum levels of fibrosis biomarkers measured early after liver transplantation are associated with severe hepatitis C virus recurrence. Transplant Infectious Disease, 2009, 11, 183-188.	1.7	26
202	High rate of infection and immune disorders in patients with hepatitis C virus after liver transplantation. Transplant Infectious Disease, 2009, 11, 367-372.	1.7	4
203	Insulin Resistance Is Associated With Advanced Liver Fibrosis and High Body Mass Index in HIV/HCV-Coinfected Patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2009, 50, 109-110.	2.1	22
204	Immunological predictors of CD4+T cell decline in antiretroviral treatment interruptions. BMC Infectious Diseases, 2008, 8, 20.	2.9	1
205	Negative influence of age on CD4+ cell recovery after highly active antiretroviral therapy in naÃ¯ve HIV-1-infected patients with severe immunodeficiency. Journal of Infection, 2008, 56, 130-136.	3.3	12
206	Association between Exposure to Nevirapine and Reduced Liver Fibrosis Progression in Patients with HIV and Hepatitis C Virus Coinfection. Clinical Infectious Diseases, 2008, 46, 137-143.	5.8	53
207	Lipid and Apoprotein Profile in HIV-1-Infected Patients After CD4-Guided Treatment Interruption. Journal of Acquired Immune Deficiency Syndromes (1999), 2008, 48, 455-459.	2.1	12
208	Immunological Recovery and Metabolic Disorders in Severe Immunodeficiency HIV Type 1-Infected Children on Highly Active Antiretroviral Therapy. AIDS Research and Human Retroviruses, 2008, 24, 1477-1484.	1.1	11
209	Long-term response to highly active antiretroviral therapy with lopinavir/ritonavir in pre-treated vertically HIV-infected children. Journal of Antimicrobial Chemotherapy, 2007, 61, 183-190.	3.0	11
210	Short Communication: Immune Reconstitution after Autologous Peripheral Blood Stem Cell Transplantation in HIV-Infected Patients: Might Be Better Than Expected?. AIDS Research and Human Retroviruses, 2007, 23, 543-548.	1.1	24
211	SLOW PROGRESSION OF HUMAN IMMUNODEFICIENCY VIRUS AND HEPATITIS C VIRUS DISEASE IN A COHORT OF COINFECTED CHILDREN. Pediatric Infectious Disease Journal, 2007, 26, 846-849.	2.0	20
212	Functional patterns of HIV-1-specific CD4 T-cell responses in children are influenced by the extent of virus suppression and exposure. Aids, 2007, 21, 23-30.	2.2	20
213	Long-Term Response to Highly Active Antiretroviral Therapy in Human Immunodeficiency Virus and Hepatitis C Virus Coinfected Children. Pediatric Infectious Disease Journal, 2007, 26, 1061-1064.	2.0	9
214	NK Cell Increase in Neonates from the Preterm to the Full-Term Period of Gestation. Neonatology, 2007, 92, 158-163.	2.0	27
215	Persistence of proinflammatory response after severe respiratory syncytial virus disease in children. Journal of Allergy and Clinical Immunology, 2007, 119, 1547-1550.	2.9	19
216	Identification of liver fibrosis in HIV/HCV-coinfected patients using a simple predictive model based on routine laboratory data. Journal of Viral Hepatitis, 2007, 14, 070901052026008-???.	2.0	28

#	Article	IF	Citations
217	Long-Term Effects of Highly Active Antiretroviral Therapy in Pretreated, Vertically HIV Type 1-Infected Children: 6 Years of Follow-Up. Clinical Infectious Diseases, 2006, 42, 862-869.	5.8	73
218	Interleukin (IL)-1Î², IL-6 and IL-8 in nasal secretions: a common role for innate immunity in viral bronchial infection in infants?. British Journal of Biomedical Science, 2006, 63, 173-175.	1.3	5
219	LOW IMMUNOLOGIC RESPONSE TO HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN NAIVE VERTICALLY HUMAN IMMUNODEFICIENCY VIRUS TYPE 1-INFECTED CHILDREN WITH SEVERE IMMUNODEFICIENCY. Pediatric Infectious Disease Journal, 2006, 25, 365-368.	2.0	15
220	CD4+ T-Cell Immunodeficiency Is More Dependent on Immune Activation Than Viral Load in HIV-Infected Children on Highly Active Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2006, 42, 269-276.	2.1	25
221	Impact of long-term viral suppression in CD4+ recovery of HIV-children on Highly Active Antiretroviral Therapy. BMC Infectious Diseases, 2006, 6, 10.	2.9	10
222	Effects of highly active antiretroviral therapy with nelfinavir in vertically HIV-1 infected children: 3 years of follow-up. Long-term response to nelfinavir in children. BMC Infectious Diseases, 2006, 6, 107.	2.9	8
223	Different profiles of immune reconstitution in children and adults with HIV-infection after highly active antiretroviral therapy. BMC Infectious Diseases, 2006, 6, 112.	2.9	29
224	Effectiveness and Safety of Abacavir, Lamivudine, and Zidovudine in Antiretroviral Therapy-Naive HIV-Infected Patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2006, 41, 154-159.	2.1	18
225	Clinical Outcomes Improve with Highly Active Antiretroviral Therapy in Vertically HIV Typeâ€1â€“Infected Children. Clinical Infectious Diseases, 2006, 43, 243-252.	5.8	72
226	Interleukin-7 levels before highly active antiretroviral therapy may predict CD4+ T-cell recovery and virological failure in HIV-infected children. Journal of Antimicrobial Chemotherapy, 2006, 57, 798-800.	3.0	11
227	Antiretroviral activity and safety of lopinavir/ritonavir in protease inhibitor-experienced HIV-infected children with severe-moderate immunodeficiency. Journal of Antimicrobial Chemotherapy, 2006, 57, 579-582.	3.0	15
228	Lopinavir/r versus Nelfinavir as Salvage Therapy. Pediatric Infectious Disease Journal, 2005, 24, 392-393.	2.0	1
229	Mutations at codons 54 and 82 of HIV protease predict virological response of HIV-infected children on salvage lopinavir/ritonavir therapy. Journal of Antimicrobial Chemotherapy, 2005, 56, 1081-1086.	3.0	13
230	Immunological Changes after Highly Active Antiretroviral Therapy with Lopinavirâ€“Ritonavir in Heavily Pretreated HIV-Infected Children. AIDS Research and Human Retroviruses, 2005, 21, 398-406.	1.1	10
231	Homeostatic role of Iâ€7 in HIVâ€1 infected children on HAART: Association with immunological and virological parameters. Acta Paediatrica, International Journal of Paediatrics, 2005, 94, 170-177.	1.5	7
232	Homeostatic role of IL-7 in HIV-1 infected children on HAART: Association with immunological and virological parameters. Acta Paediatrica, International Journal of Paediatrics, 2005, 94, 170-177.	1.5	9
233	Impact of Highly Active Antiretroviral Therapy on CD4+ T Cells and Viral Load of Children with AIDS: A Population-Based Study. AIDS Research and Human Retroviruses, 2004, 20, 927-931.	1.1	6
234	CD38 Expression in CD8+T Cells Predicts Virological Failure in HIV Type 1â€“Infected Children Receiving Antiretroviral Therapy. Clinical Infectious Diseases, 2004, 38, 412-417.	5.8	48

#	Article	IF	Citations
235	Extensive Implementation of Highly Active Antiretroviral Therapy Shows Great Effect on Survival and Surrogate Markers in Vertically HIV-Infected Children. Clinical Infectious Diseases, 2004, 38, 1605-1612.	5.8	34
236	Positive virological outcome after lopinavir/ritonavir salvage therapy in protease inhibitor-experienced HIV-1-infected children: a prospective cohort study. Journal of Antimicrobial Chemotherapy, 2004, 54, 921-931.	3.0	21
237	Virological phenotype switches under salvage therapy with lopinavirâ€“ritonavir in heavily pretreated HIV-1 vertically infected children. Aids, 2004, 18, 247-255.	2.2	24
238	HIV-infected children with moderate/severe immune-suppression: changes in the immune system after highly active antiretroviral therapy. Clinical and Experimental Immunology, 2004, 137, 570-577.	2.6	41
239	Immunity in HIV-1-Infected Adults with a Previous State of Moderate-Severe Immune-Suppression and More Than 500 CD4+ T Cell After Highly Active Antiretroviral Therapy. Journal of Clinical Immunology, 2004, 24, 379-388.	3.8	16
240	Salvage Lopinavir-Ritonavir Therapy in Human Immunodeficiency Virus-Infected Children. Pediatric Infectious Disease Journal, 2004, 23, 923-930.	2.0	41
241	Characterizing the immune system after long-term undetectable viral load in HIV-1-infected children. Journal of Clinical Immunology, 2003, 23, 279-289.	3.8	21
242	Increased interleukin-7 plasma levels are associated with recovery of CD4+ T cells in HIV-infected children. Journal of Clinical Immunology, 2003, 23, 401-406.	3.8	21
243	Stimulated proliferative responses in vertically HIV-infected children on HAART correlate with clinical and immunological markers. Clinical and Experimental Immunology, 2003, 131, 130-137.	2.6	5
244	Preserved immune system in long-term asymptomatic vertically HIV-1 infected children. Clinical and Experimental Immunology, 2003, 132, 105-112.	2.6	26
245	Recovery of T-cell subsets after antiretroviral therapy in HIV-infected children. European Journal of Clinical Investigation, 2003, 33, 619-627.	3.4	6
246	Neuroprotective effects of early antiretrovirals in vertical HIV infection. Pediatric Neurology, 2003, 29, 218-221.	2.1	32
247	Low Blood CD8+ T-Lymphocytes and High Circulating Monocytes Are Predictors of HIV-1-Associated Progressive Encephalopathy in Children. Pediatrics, 2003, 111, e168-e175.	2.1	56
248	Viral Load and CD4+ T Lymphocyte Response to Highly Active Antiretroviral Therapy in Human Immunodeficiency Virus Type 1-Infected Children: An Observational Study. Clinical Infectious Diseases, 2003, 37, 1216-1225.	5.8	54
249	CD8+ T-Cell Numbers Predict the Response to Antiviral Therapy in HIV-1-Infected Children. Pediatric Research, 2003, 53, 309-312.	2.3	7
250	CD8+ T-Cell Numbers Predict the Response to Antiviral Therapy in HIV-1-Infected Children. Pediatric Research, 2003, 53, 309-312.	2.3	6
251	Characterizing Immune Reconstitution after Long-Term Highly Active Antiretroviral Therapy in Pediatric AIDS. AIDS Research and Human Retroviruses, 2002, 18, 1395-1406.	1.1	32
252	Impact of antiretroviral protocols on dynamics of AIDS progression markers. Archives of Disease in Childhood, 2002, 86, 119-124.	1.9	19

#	Article	IF	Citations
253	Dynamics of progression markers in a nonâ€study population of human immunodeficiency virusâ€1 vertically infected infants with different antiretroviral treatments. Acta Paediatrica, International Journal of Paediatrics, 2002, 91, 776-782.	1.5	4
254	Dynamics of progression markers in a non-study population of human immunodeficiency virus-1 vertically infected infants with different antiretroviral treatments. Acta Paediatrica, International Journal of Paediatrics, 2002, 91, 776-782.	1.5	4
255	Immunological recovery after 3 yearsâ€™ antiretroviral therapy in HIV-1-infected children. Aids, 2002, 16, 483-486.	2.2	21
256	NaÃ¯ve and memory CD4+ T cells and T cell activation markers in HIV-1 infected children on HAART. Clinical and Experimental Immunology, 2001, 125, 266-273.	2.6	35
257	Antibodies to an Epitope from the Cha Human Autoantigen Are Markers of Chagas' Disease. Vaccine Journal, 2001, 8, 1039-1043.	2.6	32
258	Association of CD8+T Lymphocyte Subsets with the Most Commonly Used Markers to Monitor HIV Type 1 Infection in Children Treated with Highly Active Antiretroviral Therapy. AIDS Research and Human Retroviruses, 2001, 17, 525-532.	1.1	22
259	Disruption in cytokine and chemokine production by Tâ€cells in vertically HIVâ€1â€infected children. Acta Paediatrica, International Journal of Paediatrics, 2001, 90, 989-997.	1.5	11
260	Disruption in cytokine and chemokine production by T-cells in vertically HIV-1-infected children. Acta Paediatrica, International Journal of Paediatrics, 2001, 90, 989-997.	1.5	8
261	Impaired interleukin-5 (IL-5) production by T cells as a prognostic marker of disease progression in human immunodeficiency virus type 1 (HIV-1)-infected children. European Cytokine Network, 2001, 12, 253-9.	2.0	7
262	Tumor necrosis factor-alpha and nitric oxide in vertically HIV-1-infected children: implications for pathogenesis. European Cytokine Network, 2001, 12, 437-44.	2.0	10
263	CorrelaciÃ³n entre carga viral elevada y concentraciones de TNF-Î± y cICAM-1 en el plasma de niÃ±os infectados por el VIH-1. Anales De PediatrÃa, 2000, 52, 501-506.	0.2	5
264	Clinical Relevance of Cytokine Production in HIVâ€1 Infection in Children on Antiretroviral Therapy. Scandinavian Journal of Immunology, 2000, 52, 634-640.	2.7	0
265	Clinical Relevance of Cytokine Production in HIV-1 Infection in Children on Antiretroviral Therapy. Scandinavian Journal of Immunology, 2000, 52, 634-640.	2.7	11
266	Predictive Markers of Clinical Outcome in Vertically HIV-1â€“Infected Infants. A Prospective Longitudinal Study. Pediatric Research, 2000, 47, 509-515.	2.3	51
267	Correlation of Viral Load and CD8 T-Lymphocytes with Development of Neurological Manifestations in Vertically HIV-1-Infected Infants. A Prospective Longitudinal Study. Neuropediatrics, 1999, 30, 197-204.	0.6	20
268	Metabolic Profiling at COVID-19 Onset Shows Disease Severity and Sex-Specific Dysregulation. Frontiers in Immunology, 0, 13, .	4.8	14
269	Hepatitis E Virus Seroprevalence is Associated with Neurodegenerative Disorders in Older People with Dementia: A Case-Control Study. Journal of Infectious Diseases, 0, , .	4.0	2